jCyte
Newport Beach
About jCyte
jCyte is a developer of cell-based technology intended to cure retinitis pigmentosa. The company's therapy used retinal progenitor cells can secrete growth factors to rescue damaged retinal cells which help in treating a degenerative eye disease that ultimately causes blindness enabling, patients afflicted by conditions that lead to blindness, preserve and restore sight. They focused on the application of progenitor cell-based technology in retinal diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $3.9M
- Last round: Series Unknown (Mar 2019)
- Website: jcyte.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Information Technology
Social Profiles
Canonical: https://fsome.com/organization/jcyte-110638 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.